CHAPTER 1

Wound healing and scar formation

Simon R. Myers and Ali M. Ghanem
Department of Plastic Surgery, Barts and the London School of Medicine and Dentistry, London, UK

TYPE I – CLASSICAL CUTANEOUS WOUND HEALING

A wound, in the context of skin, is a breach in the barrier that distinguishes an organism from its environment. The process through which the organism works in order to address this breach is 'wound healing' which, because of the important role the skin plays in the survival of the organism, is quite literally vital, and conserved through evolution. In the normal course of events, a lower species accepts tissue loss and heals a wound by exposure, licking, picking and, at the molecular level, scarring. The single most important impact on wound healing in humans is the early closure of wounds, by apposition with sutures in incisional wounds, and skin replacement in excisional wounds. Humans can deny significant skin and composite tissue loss by a 'like for like' replacement in the specialty of plastic and reconstructive surgery, and here we can boast a form of 'supranormal wound healing'.[1]

Wound healing classifications

There are many ways to classify wound healing. In simple terms, we can consider:

- four phases – coagulation, inflammation, fibroplasia and remodeling;
- four types – fetal, adult, acute and chronic;
- four ages – young, plateau, regressing, atrophic; and
- two systems of healing – epidermal and dermal.

We can also classify wound healing in terms of clinical features and their wound management.

Phases of wound healing

Wound healing can be considered a process of four sequential but overlapping phases by which the body closes a breach in tissue continuity. There are many ways to define such a complex process. Key to understanding the standard classification of the process is a consideration of: the timing, the cellular activation or influx and the chemical mediators.[2]

Coagulation

This *immediate* response to cutaneous injury involves two cascades: the clotting cascade, with the formation of platelet clot which adheres to the collagen exposed following endothelial disruption; and the complement cascade and complement-mediated vasodilatation. Histamine (released by mast cell degranulation) and kinins contribute to vasodilatation and increased vascular permeability. The first cells involved then are platelets and mast cells, and the first mediators histamine, kinins, platelet-derived growth factor (PDGF) and transforming growth factor beta (TGF-β). The increasing interest in platelet-rich plasma (PRP) clinically in regenerative medicine is based on these early cascades.

Inflammation

Between the time of injury and around 4 days post injury, the clinical signs of inflammation develop. Classically these are redness, swelling, pain and loss of function. These result from inflammatory mediators and the capillary leak into the extracellular space that they coordinate. The next inflammatory cell type to arrive at the wound is the macrophage, followed by neutrophils and then lymphocytes. Keratinocytes in the wound edge and follicle remnants migrate and proliferate, and fibroblasts are chemo-attracted, and become activated.

Fibroplasia

From day 4, and for 2–4 weeks, the wound bed becomes vascularized, and type III collagen is laid down by fibroblasts to replace any dermal loss. In the absence of epidermal cover, this appears clinically as granulation tissue. Closed wounds become red and raised for a while. Hydrated glycosaminoglycans form a ground substance for the collagen fibrils. This phase is characterized by fibroblast proliferation, but also by keratinocyte proliferation.

Plastic and Reconstructive Surgery: Approaches and Techniques, First Edition. Edited by Ross D. Farhadieh, Neil W. Bulstrode and Sabrina Cugno.

Remodelling

From a few weeks to 18 months or more, the wound goes through a long phase of remodeling. Fibroblasts mature into myofibroblasts to contract the wound. Type III collagen is gradually replaced by type I collagen. Disorganized collagen becomes lamellar.

Repair versus regeneration

There are significant differences between the wound healing seen in fetal life and that seen in postnatal life. So-called scarless healing occurs for a period in the fetus, however this is not absolute but dependent on gestational age and wound size.[3] In late fetal life scarring does occur, and before this point in time, a large enough wound will still result in scarring. In postnatal life, scarring is the inevitable and permanent consequence of wounding beyond the epidermal basement membrane. An adult lower vertebrate such as a salamander can regenerate an amputated limb but will not aspire to climb Mount Everest or graduate from Oxford! Although regenerative medicine attempts to harness the same plasticity seen in lower vertebrate regeneration, what is generally achieved is only 'partial regeneration', and not replacement of like with like. The ongoing concern in work to manipulate adult/somatic stem cells to achieve true regeneration is around a loss of control and the risk of carcinogenesis.

Acute versus chronic wound healing

Acute wound healing is hard to distinguish absolutely from chronic wound healing, and the processes at a cell and molecular level may be similar.[4] Chronic wound healing occurs when healing takes longer than might be anticipated in a fit, healthy person, and is often associated with comorbidity. Such wounds seem to become stuck in the inflammatory or proliferative/fibroplastic phases. Local wound management can only usefully begin following an assessment and optimization of systemic comorbid conditions.

Epithelial/epidermal versus mesenchymal/dermal wound healing

The epidermis provides the ultimate barrier between the body and environment. The main cell type is the keratinocyte. Regeneration occurs from a population of follicle stem cells.[5] The dermis provides the structural support to the epidermis and other related adnexae. The main dermal cell type is the fibroblast. As in embryogenesis, there is ongoing 'cross-talk' between the epidermis and dermis in somatic cutaneous wound healing, the epidermal element of which has been relatively underplayed. Even less consideration has been given to the contribution of subcutaneous fat to cross-talk.

Wound healing and scarring

In many ways, wound healing and scarring are inseparable – the one leads to the other at some level and over time. When does a wound become a scar? That will probably depend at a molecular level on very early wounding and wound management events. Although a scar is the inevitable and permanent consequence of postnatal wounding beyond the basement membrane and a compromise between regeneration and repair, at a clinical level, its significance is largely patient related and subjective. This can now be captured clinically by the Patient and Observer Scar Assessment Scale (POSAS), which draws patients into their own management.[6]

Most patients would perceive a wound as a scar from the time that the wound is no longer open, and often that equates to the absence of exudate and any requirement for dressing care. Clinically, even a normotrophic scar will go through a natural progression to maturity. When young, it will be active. Most young scars exhibit features of hypertrophy. Most scars then go through a plateau period of relatively little clinical change in the absence of treatment. Most scars then go through a period of regression of inflammatory signs and symptoms, and eventually settle to a mature state. Some scars, after many months or years, and sometimes because of treatment, become very thin, pale and atrophic.

When then does a normotrophic scar become a pathological scar? A normotrophic scar results from uneventful primary healing, but there is wide variation with age, site and skin type, and a period of hypertrophy is not unusual. Hypertrophic scarring is classically seen in paediatric burn wounds that have struggled to heal.[7] The scar becomes red, raised, painful and itchy around 2–3 months following wound closure, particularly in wounds that have taken more than three weeks to heal. The scar settles over 18 months to 2 years, but often incompletely. Hypertrophic scars occur particularly in extreme Fitzpatrick skin types. Presumably, there is a bell curve distribution within the population, where those at the extreme end of hypertrophic scarring could be termed pathological. Although a keloid scar shares many of the features of a hypertrophic scar, and may represent an extreme example of the same, it is defined by extension beyond the confines of the injury, by almost inevitable progression beyond 2 years, seldom regressing; by being refractory to most treatments and recurring within 4–6 months of cessation of most treatments; and by behaving pathologically like a benign tumour. Understanding such an extreme phenotype may prove key to the effective management of more normotrophic scarring.

Epidermal wound healing

Adult epidermal stem cell biology is relatively well understood. Keratinocyte stem cells reside primarily in the bulge region of the hair follicle and, by asymmetric division, populate the interfollicular basement membrane with transit amplifying cells.[8] These divide a number of times to provide the differentiating cells of the stratifying epidermis. A huge array of small

peptides are involved in coordinating the response to epidermal wounding by autocrine, paracrine and juxtacrine signaling.[9] In a human model of epidermal healing, a number of phases of keratinocyte activity are suggested, as shown in Figure 1.1.[10]

Acute activation

Almost immediately following wounding, the epidermis expresses interleukin 1β (IL-1β) and interleukin 6 (IL-6) and the dermis TGF-β1, committing transit amplifying cells to mitosis. Although TGB-β1 is antiproliferative, it is pro-migratory to keratinocytes.[11]

Early activation

Towards 24 h following wounding, keratinocyte proliferation and migration are clear. Epidermal expression of TGF-α and IL-6 is accompanied by dermal fibroblast keratinocyte growth factor (KGF) and IL-6 expression. A paracrine loop of epidermal IL-1β induction of the potent keratinocyte mitogen KGF from dermal fibroblasts seems likely.[12] TGF-α both is a keratinocyte mitogen and induces the migratory K6/K16 keratinocyte cytoskeletal phenotype in the suprabasal compartment.[13] It may also recruit nearby follicles by juxtacrine signalling.[14]

Restitution

Over weeks, homeostasis is restored, with relatively late activation of the bulge to restore the transit amplifying population.

Dermal wound healing

Wound healing studies have concentrated far more on the dermis than epidermis, and particularly on macrophage production of TGF-β isoforms. This multifunctional growth factor appears to play a key role in dermal healing and scarring.[15] Although the TGF-β1 isoform promotes scarring, the TGF-β3 isoform appears to have the opposite effect.[16] Juvista (Avotermin) was developed to improve the quality of normotrophic scarring, but failed in a European phase 3 clinical trial.[17] TGF-β, however, remains a key pharmaceutical target.



Figure 1.1 Temporo-spatial cytokine and growth factor gene expression in human suction blister wound healing. TGF, transforming growth factor; KGF, keratinocyte growth factor; relative OD, relative optical density.

A preoccupation with one growth factor, albeit a powerful, multifunctional factor with isoforms of different action, and for each a dose-dependent heterogeneity of responses, is arguably to ignore the complexity of wound healing cascades. There are many factors at play, often pleiotropic, and there is significant redundancy – so that many factors can contribute to the same outcome (i.e. rapid closure by scar). The growth factor that has shown most promise when delivered alone is PDGF.[18]

The dermis is far more than an extracellular matrix populated by fibroblasts. It hosts a vascular network (arterial, venous and lymphatic) and a neural network, and supports the follicle and other adnexal stem cell niches. It must also, it seems, interact with the subcutaneous fat. One approach to tissue engineering to provide for wound tissue loss is to synthesize an appropriate nanotechnology scaffold for key cellular elements to populate and develop. This can be *biofunctionalized* by incorporating a latent growth factor.[19]

Wounds can be classified based on clinical management and outcome as shown in Table 1.1.

'Normal'/primary incisional wound healing (type Ia)

Incisional wound healing occurs following surgical access, or 'incisional' or lacerating trauma.[20] In the former, the wound will begin sterile, and in the latter some degree of contamination is usual. In neither instance is there significant tissue loss. Classically, in modern medical practice, these wounds are formally closed, although the timing of that closure will vary, affecting the quality of the healing processes and the scar that results.

Early closure (type Iai)

If an incisional wound is closed directly, the healing will tend to be optimal. Elective surgical wounds are closed at the end of the procedure performed under sterile conditions. Traumatic lacerating wounds will generally be cleaned and closed the same day, and before significant bacterial colonization occurs. A relatively arbitrary time limit to early closure has evolved in practice of 48 h from injury. Beyond this, it is considered likely that colonization may be significant enough to deleteriously affect healing, and as a consequence the quality of scarring, which may become hypertrophic.

Late closure (type Iaii)

If a type Ia wound is sutured after 48 h, wound colonization may result in infection, dehiscence and delayed healing. Counterintuitively, according to current dogma if the wound is left open until day 4 or 5, as in 'delayed primary closure', satisfactory results can be achieved at a stage when the inflammatory response has become established – although a recent Cochrane review found no evidence for this.[21]

No closure (type Iaiii)

An incisional wound beyond the epidermal basement membrane that is left unclosed will gape and behave much like a deep excisional wound, healing by classical 'secondary intent'.[22] The time

Table 1.1 A revised wound classification based on clinical management and outcome

Type I: Classical	Wound ± intervention	Character of healing
(a) 'Normal'/primary incisional – incisional, no tissue loss	(i) Closed early (<48 h)	Low risk of infection Minimal line scar
	(ii) Closed late (>48 h)	Increased risk infection Increased risk chronicity More significant scar
	(iii) Unclosed	Healing by granulation (similar to type Ibii), but in absence of tissue loss) High risk of chronicity
'Normal'/secondary excisional – tangential tissue loss, no replacement	(i) Above mid-dermis	Rapid re-epithelialization (<10 days) Minimal clinical scar
	(ii) Below mid-dermis	Slow/absent re-epithelialization High risk of infection and chronicity Closure by scar
Type II: Neoclassical		
(a) 'Supranormal' by skin replacement	(i) Early split- or full-thickness skin grafting of type Ibii)	Present gold standards Cosmetic and functional problems remain Donor defect
	(ii) Biotechnological skin replacements (Cuono technique, *in vitro* composite grafts)	Ideally autologous and with viable cellular elements Opportunity to improve on types Ibii and IIai
(b) 'Supranormal' with apparent acceptance of tissue loss	(i) Type Ibi treated with cultured keratinocyte allografts or vapour-permeable membrane (ii) Chronic full-thickness wound treated with cultured keratinocyte allografts or vapour-permeable membrane	Follicle recruitment by activated extended follicle units Simulation of an acute wound environment

to healing will be slow, because closure will rely on wound base contraction and edge re-epithelialization. As a consequence, the quality of the scar will tend to 'pathological'.

'Normal'/secondary excisional wound healing (type Ib)

Where surgery requires skin excision, or cutaneous trauma is tangential (e.g. burn injury or friction loss) and the tissue loss is not replaced, then the time to healing and the scar quality will depend on the depth of the loss. Re-epithelialization and restoration of barrier function from adnexal remnants will be slower, the deeper the injury.

Above mid-dermis (type Ibi)

Tangential tissue loss above the mid-dermis leaves a partial-thickness wound that will heal in around one week under ideal circumstances, and result in a 'controllable' scar – as in the surgical split-thickness skin graft donor site. If a traumatic tangential injury clearly reaches the mid-dermis acutely (i.e. a mid-dermal burn injury), then optimal wound management is key to prevent extension of the tissue loss to type Ibii. In extreme Fitzpatrick types, even these type Ibi wounds can scar pathologically.

Below mid-dermis (type Ibii)

Tangential tissue loss below the mid-dermis leaves a partial-thickness wound that will take three weeks or more to heal, and as a consequence will be more liable to chronicity and significant scarring.[7] It is at this depth, or beyond, that intervention is considered. A full-thickness defect can only re-epithelialize from the wound edge, and will otherwise close substantially by scar contraction of the base.

Abnormal wound healing

Systemic and local factors may reduce the quality of the skin and/or affect wound healing adversely. These are important to recognize and optimize.

Systemic factors

Systemic factors may be congenital or acquired. There are a handful of congenital conditions that affect the processes of healing, and in some instances the clinical quality of the skin and healing. A range of defects in collagen synthesis is seen in Ehlers–Danlos syndrome, and healing is poor.[23] The skin is vulnerable, and healing slow in epidermolysis bullosa, where for example, in the junctional variant, laminin 5 is deficient in the epidermal basement membrane zone.[24] The autosomal recessive premature ageing condition progeria manifests many features of normal 'acquired' ageing.[25]

With age, the changes in healing processes are fairly global, resulting in a delay in wound closure and a reduction in wound strength. How much these changes are the result of increasing comorbidities associated with age, rather than age itself, is not entirely clear. Other acquired systemic factors include: nutrition, drugs, diabetes and smoking. Vitamin C deficiency is the classical example of a nutritional factor involved in wound healing. Although scurvy is not likely with Western diets, vitamin C is an essential cofactor for collagen synthesis. Vitamin A deficiency is also rare in the developed world, but vitamin A can reverse steroid-induced collagenase activity. Zinc is important to many enzyme systems, and deficiency can be seen in large burn injury. In those same injuries, albumin can plummet to around 10 g/L, and although this will delay healing, closure can be achieved.

Obesity is epidemic now in the Western world, and associated with many comorbidities and wound complications following surgery.[26] Plastic surgery reconstructions following bariatric surgery are challenging. Large blood vessels will have developed to support the tissue volume, and these may contribute to postoperative bleeding complications. Despite these hypertrophic vessels, tissue perfusion may be poor, and the tissue lymphoedematous and critically colonized. Furthermore, closure after such excisional surgery is by definition under tension, so that infection and dehiscence are more common.

Anti-inflammatory systemic glucocorticoids, non-steroidal anti-inflammatory drugs and chemotherapy drugs globally suppress the cellular responses to wounding. Chemotherapeutic angiogenesis inhibitors, such as bevacizumab, a vascular endothelial growth factor-neutralizing antibody fragment used in colonic cancer, cannot be prescribed six weeks before or after surgery to limit the wound healing risks.[27]

Diabetes mellitus may affect healing in a variety of complex ways, particularly in the lower limbs. Patients with diabetes are susceptible to atherosclerosis in larger vessels, and tissue oxygen delivery is further reduced by the stiffness of the red blood cells, and the higher oxygen affinity of glycosylated haemoglobin.[28] These effects are compounded by any neuropathy, and impaired cellular immunity, phagocytosis and bacterial killing.

Smoking may affect wound healing in both immediate and longer term ways.[29] Nicotine causes sympathetic vasoconstriction, and carbon monoxide shifts the oxygen dissociation curve to the left. Long-term smoking accelerates atherosclerotic changes. Smoking appears to be a particular problem in surgery to superficial soft tissue planes, where wide skin undermining with the sacrifice of multiple perforators, and closure under tension are combined, as in abdominoplasty surgery.

Local factors

One of the most controllable local factors for incisional wounds is surgical technique and the handling of tissue. Tissue handling within the specialty can be observed, par excellence, under the microscope during a microvascular anastomosis, where poor

handling results in anastamotic thrombosis.[30] Local factors often reflect systemic comorbidities, so that poor blood supply and oxygen delivery, and even critical bacterial colonization are more often than not a local manifestation of a systemic factor. Conversely, the radiotherapy that results in local thromboendarteritis obliterans and causes healing problems over time may also have systemic effects.[31] In terms of recurrence, radiotherapy is the most effective treatment for keloid scars, damping down the 'overhealing' provided it follows extralesional excision directly.[32] Breaches in the skin are inevitably colonized by commensals. With time and increasing bacterial number, the body mounts an inflammatory response, and the colonization is termed critical. Critical colonization is not anticipated until around 48 h as a rule of thumb. Once 10^5 organisms are present per gram of tissue, the wound may be considered infected. Chronicity and some level of colonization go hand in hand. Bacterial biofilms are prevalent in chronic wounds, including anaerobic organisms not isolated by standard culture systems, and this is an area of particular current interest in such wounds[33] – and also of course in subcutaneous/cavity wounding and scarring (e.g. breast capsular contracture).[34]

Mechanotransduction

There is a sense that the skin is constantly subclinically injured to some degree by sheer forces, and indeed even the force of gravity.[35] This may drive the baseline turnover of the skin. The effects of physico-mechanical forces on cell behavior, termed *mechanotransduction*, are becoming increasingly recognized and understood in wound healing.[36] In 1861, Karl Langer observed that the skin exhibits intrinsic tension,[37] and Langer's lines, defined by the direction in which circular excisional wounds will elongate to ellipses by anatomic site, are used today to orientate excisional surgery. *Tensegrity* describes the way in which mechanical forces regulate biological systems via perturbations in structural architecture; disruption of tensional integrity triggers cellular pathways that restore mechanical homeostasis.[38] Cells also actively generate intracellular tension, *cell traction forces*, as they interact with their environment during, for example, migration.[39] A cell-centric view of mechanotransduction is, however, inadequate. Conformational changes in the extracellular matrix by mechanical forces can reveal cryptic binding sites and expose growth factors. Non-structural, extracellular, *matricellular* proteins (e.g. connective tissue growth factor) are increasingly implicated in the regulation of healing and scar formation.[40] Mechanosensing in the skin is a feature not just of fibroblasts but also of keratinocytes and nociceptors. It is quite possible that physical cues during wound healing direct, in part, stem cell fate within that niche.

Any therapeutic effects of silicone gels, pressure garments and linear taping may work through mechanical offloading and mechanotransduction pathways. The use of Botox A to control tension across healing facial scars and improve scar quality is an interesting new approach.[41] Vacuum-assisted closure has become a common approach to complex wound management, and although poorly understood, must rely to a large extent on mechanotransduction.

TYPE II – NEOCLASSICAL CUTANEOUS WOUND HEALING

'Supranormal' healing by skin replacement (type IIa)

Classically, intervention to close a wound was sometimes considered 'tertiary' wound healing. The great variety of techniques now available suggest a more structured classification.

Early split-thickness or full-thickness skin grafting of type Ibii (type IIai)

Those tangential traumatic or excisional wounds that are unlikely to heal in a reasonable timescale and are therefore likely to scar are most commonly closed with split-thickness skin autograft. Where the wound is full thickness, the environment optimal and the defect limited in size, a full-thickness autograft will provide a superior reconstruction. Of course, any number of local and distant skin and fasciocutaneous flaps are considered for defects that have resulted in an ungraftable bed, and this category of skin replacement feeds into other classifications of flap reconstruction. Skin and fasciocutaneous free flaps are increasingly being used to close defects in hostile comorbid conditions (e.g. in 'vasculoplastics' practice).[42]

Biotechnological skin replacements (type IIaii)

In recent years, products, often xenograft in nature, have been developed to provide the quality of a full-thickness graft reconstruction from a split-thickness skin graft donor site. 'Dermal regeneration templates', such as Integra, engraft to provide a 'neodermis' to support a thin autograft in two operative stages.[43] A single-stage Integra system has been available following the success of single-stage Matriderm grafting.[44] Included here also is the system developed by Cuono and colleagues that combines allograft dermis with autologous cultured keratinocytes in the closure of full-thickness burn excision beds.[45] Cultured keratinocyte technology represents one of the most established forms of somatic stem cell therapy, and sits most coherently within plastic and reconstructive surgery.

'Supranormal' healing with apparent acceptance of tissue loss (type IIb)

When tangential tissue loss is accepted and no apparent attempt is made to replace like with like to the level of loss, then there are still interventions that seem to present some clinical advantage. George Winter presented his understanding of tangential wound healing in a porcine partial-thickness

excisional model that included both edge and base contributions to restoration of epidermal barrier function, and introduced the world to the concept of 'moist wound healing'. This spawned a massive industry in moist wound healing dressing systems, initially vapour-permeable membranes.[46] Although this transformed the 'dry' wound management of the time, it has not proven a panacea, and far more sophisticated biological systems have evolved since (see below). The clinical evidence base for these, however, has been slow to evolve on a cost basis, and so marketplaces have yet to develop around economy of scale.

Type Ibi treated with cultured keratinocyte allograft or biological dressing (type IIbi)

Cultured keratinocyte allografts have been used for decades to accelerate partial-thickness wound healing.[47] Although they do not survive transplantation long term,[48] they present a temporary and coordinated 'growth factor factory'. It may also be that they provide a juxtacrine mechanism for 'discontinuous follicle recruitment' by bridging adnexal remnants separated by tangential partial-thickness wounding.[10] Biobrane is a conforming bilayer of porcine collagen and nylon.[49] It is at least haemostatic and adheres to a clean partial-thickness wound until shed when the epidermal barrier has been restored. The evidence for its efficacy and detail of any mechanism has never been established, but a role for the limitation of colonization of adherence seems likely.

Chronic full-thickness wound treated with cultured keratinocyte allograft or biological dressing (type IIbii)

Chronic full-thickness wounds are a huge financial burden to any healthcare system, and generally associated with comorbidity.[50] Any comorbid condition should be optimized in the first instance. There then may be some further benefit from cell-based therapy or biological dressings. Both cultured keratinocyte allografts and autografts have been used to treat such wounds.[51] It is suggested that even with poor clinical autograft take, a more acute healing picture is seen, at least clinically – healing is 'kick-started'. The wound bed can be modulated with, for example, hyaluronic acid, an important component of the embryonic extracellular matrix, to improve clinical take, perhaps by supporting a niche-like stem cell environment.[52]

Fat

There has been a huge recent interest in fat grafting, not only for augmentation including following subcision of indented scars and scar-related fat atrophy, but also to improve healing and the quality of the overlying scar.[53] It is fascinating to reflect that Sir Harold Gillies may have used whole-fat grafts in acute closure of craniofacial traumatic wounds with the same intent many decades ago.[54] It has been suggested that any effect on healing and scarring results not from the grafted fat directly, much of which is lost, but from stimulation of a local mesenchymal stem cell response. The current controversy is around the method of enrichment of autologous fat to provide safe augmentation long term, and the resolution of this will run parallel with resolution of controversy around any effect on healing and scarring. A recent randomized controlled study in normal human volunteers demonstrated that enrichment of autologous fat with cultured autologous adipose-derived stem cells was significantly more effective, in graft survival terms, than a more standard approach.[55]

Lymphoedema

Lower limb lymphovenous disease is a recognized cause of recurrent cellulitis and chronic wound healing. There is a newly recognized patient base in the morbid obese and postbariatric population, and with the evolution of supra-microsurgical techniques, the promise of new therapies (e.g. lymphovenous anastomosis and lymph node transplantation).[56]

Future

Modern genomic and proteomic techniques allow us to define the processes that control tissue volume and its nature in healing at a molecular level – broadly: migration, proliferation, differentiation and apoptosis. Those techniques require very little material from biopsy, and we should expect to see more evidence from controlled longitudinal human studies available to support our understanding of the different types of healing. The sheer complexity of the pathways and interactions within countless networks will require a systiomics, or systems biology, approach, calling on applied mathematics and computer modelling. Resources to support controlled human studies of wound healing and interventions are limited in part by a perception that the area is mundane. There are, however, many gaps in our basic understanding of what are quite fundamental processes. Cell-based therapies are expensive, but will continue to offer the most rationale wound management solutions until our understanding is more complete. Longitudinal cost–benefit analyses of novel therapies remain few and far between.

References

1 Myers S. Keratinocyte growth and differentiation in cutaneous wound healing and cultured keratinocyte grafting. PhD thesis, University of London, 1999.
2 Masters in Burn Care. Queen Mary University, London.

3 Longaker MT, Whitby DJ, Adzick NS, *et al*. Studies in fetal wound healing, VI. Second and early third trimester fetal wounds demonstrate rapid collagen deposition without scar formation. *Journal of Pediatric Surgery* 1990;25:63–68; discussion 68–69.

4 Monaco JL, Lawrence WT. Acute wound healing an overview. *Clinics in Plastic Surgery* 2003;30:1–12. Review.

5 Lavker RM, Sun TT, Oshima H, *et al*. Hair follicle stem cells. *Journal of Investigative Dermatology Symposium Proceedings* 2003;8:28–38. Review.

6 Nicholas RS, Falvey H, Lemonas P, *et al*. Patient-related keloid scar assessment and outcome measures. *Plastic Reconstructive Surgery* 2012;129:648–656.

7 Deitch EA, Wheelahan TM, Rose MP, Clothier J, Cotter J. Hypertrophic burn scars: analysis of variables. *Journal of Trauma* 1983;23:895–898.

8 Bickenbach JR. Isolation, characterization, and culture of epithelial stem cells. *Methods in Molecular Biology* 2005;289:97–102.

9 Navsaria HA, Myers SR, Leigh IM, McKay IA. Culturing skin in vitro for wound therapy. *Trends in Biotechnology* 1995;13:91–100. Review.

10 Myers SR, Leigh IM, Navsaria H. Epidermal repair results from activation of follicular and epidermal progenitor keratinocytes mediated by a growth factor cascade. *Wound Repair and Regeneration* 2007;15:693–701.

11 Jeong HW, Kim IS. TGF-β1 enhances βig-h3-mediated keratinocyte cell migration through the α3β1 integrin and PI3K. *Journal of Cellular Biochemistry* 2004;92:770–780.

12 Angel P, Szabowski A. Function of AP-1 target genes in mesenchymal-epithelial cross-talk in skin. *Biochemical Pharmacology* 2002;64:949–956. Review.

13 Jiang CK, Magnaldo T, Ohtsuki M, Freedberg IM, Bernerd F, Blumenberg M. Epidermal growth factor and transforming growth factor alpha specifically induce the activation- and hyperproliferative-associated keratins 6 and 16. *Proceedings of the National Academy of Sciences of the USA* 1993;90:6786–6790.

14 Owen MR, Sherratt JA, Myers SR. How far can a juxtacrine signal travel? *Proceedings of the Royal Society B: Biological Sciences* 1999;266:579–585.

15 O'Kane S, Ferguson MW. Transforming growth factor beta s and wound healing. *International Journal of Biochemistry and Cell Biology* 1997;29:63–78. Review.

16 Occleston NL, Laverty HG, O'Kane S, Ferguson MW. Prevention and reduction of scarring in the skin by transforming growth factor beta 3 (TGFbeta3): from laboratory discovery to clinical pharmaceutical. *Journal of Biomaterials Science. Polymer Edition* 2008;19:1047–1063. Review.

17 Renovo. *Juvista EU Phase 3 trial results*. 2011. http://www.renovo.com/en/news/juvista-eu-phase-3-trial-results (accessed 23 June 2014).

18 Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers. *Plastic and Reconstructive Surgery* 2006;117(Suppl.):143S–149S; discussion 150S–151S. Review.

19 Lim EH, Sardinha JP, Myers S, Stevens M. Latent transforming growth factor-beta1 functionalised electrospun scaffolds promote human cartilage differentiation: Towards an engineered cartilage construct. *Archives of Plastic Surgery* 2013;40:676–686.

20 Singer AJ, Clark RAF. Cutaneous wound healing. *New England Journal of Medicine* 1999;341:738–746.

21 Eliya-Masamba MC, Banda GW. Primary closure versus delayed closure for non bite traumatic wounds within 24 hours post injury. *Cochrane Database of Systematic Reviews* 2013;10:CD008574.

22 Ward PD, London N, Collar R. Role of secondary intention healing. *Facial Plastic Surgery* 2013;29:346–350.

23 Whitaker IS, Rozen WM, Cairns SA, Howes J, Pope FM, Hamish Laing J. Molecular genetic and clinical review of Ehlers-Danlos Type VIIA: implications for management by the plastic surgeon in a multidisciplinary setting. *Journal of Plastic, Reconstructive & Aesthetic Surgery* 2009;62:589–594.

24 Fine JD. Inherited epidermolysis bullosa: past, present, and future. *Annals of the New York Academy of Sciences* 2010;1194:213–222.

25 Rosengardten Y, McKenna T, Grochová D, Eriksson M. Stem cell depletion in Hutchinson-Gilford progeria syndrome. *Aging Cell* 2011;10:1011–1020.

26 Albino FP, Koltz PF, Gusenoff JA. A comparative analysis and systematic review of the wound-healing milieu: implications for body contouring after massive weight loss. *Plastic and Reconstructive Surgery* 2009;124:1675–1682.

27 Lemmens L, Claes V, Uzzell M. Managing patients with metastatic colorectal cancer on bevacizumab. *British Journal of Nursing* 2008;17:944–949.

28 Tsourdi E, Barthel A, Rietzsch H, Reichel A, Bornstein SR. Current aspects in the pathophysiology and treatment of chronic wounds in diabetes mellitus. *BioMed Research International* 2013;385641.

29 Sørensen LT. Wound healing and infection in surgery: the pathophysiological impact of smoking, smoking cessation, and nicotine replacement therapy: a systematic review. *Annals of Surgery* 2012;255:1069–1079.

30 Ramachandran S, Ghanem AM, Myers SR. Assessment of microsurgery competency-where are we now? *Microsurgery* 2013;33:406–415.

31 Hubenak JR, Zhang Q, Branch CD, Kronowitz SJ. Mechanisms of injury to normal tissue after radiotherapy: a review. *Plastic and Reconstructive Surgery* 2014;133:49e–56e.

32 Ogawa R, Huang C, Akaishi S, *et al*. Analysis of surgical treatments for earlobe keloids: analysis of 174 lesions in 145 patients. *Plastic and Reconstructive Surgery* 2013;132:818e–825e.

33 Bertesteanu S, Triaridis S, Stankovic M, Lazar V, Chifiriuc MC, Vlad M, Grigore R. Polymicrobial wound infections: Pathophysiology and current therapeutic approaches. *International Journal of Pharmaceutics* 2014;463:119–126.

34 Tamboto H, Vickery K, Deva AK. Subclinical (biofilm) infection causes capsular contracture in a porcine model following augmentation mammaplasty. *Plastic and Reconstructive Surgery* 2010;126:835–842.

35 Farahani RM, DiPietro LA. Microgravity and the implications for wound healing. *International Wound Journal* 2008;5:552–561.

36 Wong VW, Akaishi S, Longaker MT, Gurtner GC. Pushing back: wound mechanotransduction in repair and regeneration. *Journal of Investigative Dermatology* 2011;131:2186–2196.

37 [No authors listed]. On the anatomy and physiology of the skin: conclusions by Professor K. Langer. *British Journal of Plastic Surgery* 1978;31:277–278.

38 Ingber DE. Tensegrity I. Cell structure and hierarchical systems biology. *Journal of Cell Science* 2003;116:1157–1173. Review.

39 Wang JH, Lin JS. Cell traction force and measurement methods. *Biomechanics and Modeling in Mechanobiology* 2007;6:361–371.

40 Eckes B, Nischt R, Krieg T. Cell-matrix interactions in dermal repair and scarring. *Fibrogenesis and Tissue Repair* 2010;3:4.
41 Ziade M, Domergue S, Batifol D, *et al.* Use of botulinum toxin type A to improve treatment of facial wounds: a prospective randomised study. *Journal of Plastic, Reconstructive & Aesthetic Surgery* 2013;66:209–214.
42 Kim CY, Kim YH. Supermicrosurgical reconstruction of large defects on ischemic extremities using supercharging techniques on latissimus dorsi perforator flaps. *Plastic and Reconstructive Surgery* 2012;130:135–144.
43 Loss M, Wedler V, Künzi W, Meuli-Simmen C, Meyer VE. Artificial skin, split-thickness autograft and cultured autologous keratinocytes combined to treat a severe burn injury of 93% of TBSA. *Burns* 2000;26:644–652.
44 Haslik W, Kamolz LP, Nathschläger G, Andel H, Meissl G, Frey M. First experiences with the collagen-elastin matrix Matriderm as a dermal substitute in severe burn injuries of the hand. *Burns* 2007;33:364–368.
45 Cuono CB, Langdon R, Birchall N, Barttelbort S, McGuire J. Composite autologous-allogenic skin replacement: Development and clinical application. *Plastic and Reconstructive Surgery* 1987;80:626–635.
46 Winter GD. Epidermal regeneration studied in the domestic pig. In: HI Maibach, DT Rovee (eds), *Epidermal Regeneration*, pp. 71–112. Chicago: Year Book Publishing; 1972.
47 Phillips TJ, Gilchrest BA. Cultured epidermal allografts as biological wound dressings. *Progress in Clinical and Biological Research* 1991;365:77–94.
48 Griffiths M, Ojeh N, Livingstone R, Price R, Navsaria H. Survival of Apligraf in acute human wounds. *Tissue Engineering* 2004;10: 1180–1195.
49 Yang JY, Tsai YC, Noordhoff MS. Clinical comparison of commercially available Biobrane preparations. *Burns* 1989;15: 197–203.
50 Harding KG, Morris HL, Patel GK. Healing chronic wounds. *British Medical Journal* 2002;324:160.
51 Phillips TJ, Gilchrest BA. Cultured epidermal grafts in the treatment of leg ulcers. *Advanced Dermatology* 1990;5:33–48; discussion 49.
52 Myers SR, Partha VN, Soranzo C, Price RD, Navsaria HA. Hyalomatrix: a temporary epidermal barrier, hyaluronan delivery, and neodermis induction system for keratinocyte stem cell therapy. *Tissue Engineering* 2007;13:2733–2741.
53 Mojallal A, Lequeux C, Shipkov C, *et al.* Improvement of skin quality after fat grafting: clinical observation and an animal study. *Plastic and Reconstructive Surgery* 2009;124:765–774.
54 Gillies HD, Millard DR. *The Principles and Art of Plastic Surgery*. Boston, MA: Little, Brown, & Company; 1957.
55 Kølle SF, Fischer-Nielsen A, Mathiasen AB, *et al.* Enrichment of autologous fat grafts with ex-vivo expanded adipose tissue-derived stem cells for graft survival: a randomised placebo-controlled trial. *Lancet* 2013;382(9898):1113–1120.
56 Koshima I, Narushima M, Yamamoto Y, Mihara M, Iida T. Recent advancement on surgical treatments for lymphedema. *Annals of Vascular Disease* 2012;5:409–415.